{"id":"NCT02573324","sponsor":"AbbVie","briefTitle":"A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification","officialTitle":"A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-01-04","primaryCompletion":"2022-04-04","completion":"2022-04-04","firstPosted":"2015-10-09","resultsPosted":"2023-05-11","lastUpdate":"2023-05-11"},"enrollment":691,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Glioblastoma","Gliosarcoma"],"interventions":[{"type":"DRUG","name":"Temozolomide","otherNames":[]},{"type":"DRUG","name":"Depatuxizumab mafodotin","otherNames":["ABT-414"]},{"type":"RADIATION","name":"Radiation","otherNames":[]},{"type":"DRUG","name":"Placebo for ABT-414","otherNames":[]}],"arms":[{"label":"Depatuxizumab Mafodotin, Radiation and Temozolomide (TMZ)","type":"EXPERIMENTAL"},{"label":"Placebo, Radiation and TMZ","type":"PLACEBO_COMPARATOR"},{"label":"Open-Label Sub-Study: Depatuxizumab Mafodotin, Radiation and TMZ","type":"EXPERIMENTAL"}],"summary":"This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification.\n\nIn addition, there is a Phase 1, open-label, multicenter sub-study to assess the pharmacokinetics, safety and tolerability of ABT-414 in participants with newly diagnosed EGFR-amplified GBM who have mild or moderate hepatic impairment.","primaryOutcome":{"measure":"Overall Survival (OS)","timeFrame":"Overall median duration of follow-up was 15.5 months (range: 0.1, 35.6).","effectByArm":[{"arm":"Placebo, Radiation and TMZ","deltaMin":18.7,"sd":null},{"arm":"Depatuxizumab Mafodotin, Radiation and TMZ","deltaMin":18.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.633"},{"comp":"OG000 vs OG001","p":"0.704"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":212,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","China","Colombia","Czechia","France","Germany","Hong Kong","Ireland","Israel","Italy","Mexico","Netherlands","New Zealand","Portugal","Russia","Singapore","South Africa","South Korea","Spain","Switzerland","Taiwan","United Kingdom"]},"refs":{"pmids":["29982805","29077941","28039367"],"seeAlso":["https://www.clinicaltrialsandme.com"]},"adverseEventsSummary":{"seriousAny":{"events":56,"n":335},"commonTop":["FATIGUE","THROMBOCYTOPENIA","NAUSEA","KERATOPATHY","CONSTIPATION"]}}